Explore

Trendline Trendline
Novanta Inc. Schedules First Quarter 2026 Earnings Release and Conference Call

Novanta Inc. Schedules First Quarter 2026 Earnings Release and Conference Call

Novanta Inc. Schedules First Quarter 2026 Earnings Release and Conference Call
Trendline Trendline
Viatris Announces Upcoming First Quarter 2026 Financial Results Release

Viatris Announces Upcoming First Quarter 2026 Financial Results Release

Viatris Announces Upcoming First Quarter 2026 Financial Results Release
Trendline Trendline
Viatris to Announce Q1 2026 Financial Results on May 7

Viatris to Announce Q1 2026 Financial Results on May 7

Viatris to Announce Q1 2026 Financial Results on May 7
Trendline Trendline
Biotech Firms Alamar, Hemab, Kailera, and Seaport Advance IPOs Amid Strong Market Start

Biotech Firms Alamar, Hemab, Kailera, and Seaport Advance IPOs Amid Strong Market Start

Biotech Firms Alamar, Hemab, Kailera, and Seaport Advance IPOs Amid Strong Market Start
Trendline Trendline
Veralto Corporation Announces First Quarter 2026 Earnings Call for Investors

Veralto Corporation Announces First Quarter 2026 Earnings Call for Investors

Veralto Corporation Announces First Quarter 2026 Earnings Call for Investors
AP News AP News
Wall Street futures are flat as US and Iran try to restart talks, but oil ticks higher

Wall Street futures are flat as US and Iran try to restart talks, but oil ticks higher

Markets on Wall Street were largely unchanged from a day earlier and oil prices rose modestly Wednesday as mediators moved closer to extending the ceasefire between the United States and Iran and restarting negotiations to salvage the fragile truce
Reuters Reuters
Allbirds shares jump over 400% on plans to pivot to AI from sneakers

Allbirds shares jump over 400% on plans to pivot to AI from sneakers

April 15 (Reuters) - Shares of Allbirds surged more than five-fold on Wednesday after the footwear maker said it was raising capital and pivoting towards AI computing infrastructure.
Reuters Reuters
J&J's first-quarter profit beats estimates even as Stelara sales disappoint

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

By Michael Erman April 14 (Reuters) - Johnson & Johnson reported first-quarter earnings that beat Wall Street expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its
AP News AP News
Wall Street tacks on more gains and crude oil falls on hopes of renewed US-Iran talks

Wall Street tacks on more gains and crude oil falls on hopes of renewed US-Iran talks

The U.S. stock market is inching closer to its all-time high and oil prices are easing as hopes continue that the global economy can avoid a worst-case scenario from the U.S.-Iran war
AP News AP News
Wall Street rises toward the edge of its all-time high as oil prices ease

Wall Street rises toward the edge of its all-time high as oil prices ease

The U.S. stock market is nearing its all-time high, and oil prices are easing as hopes rise that the United States and Iran may try again on talks to end their war
Trendline Trendline
Viatris to Announce First Quarter 2026 Financial Results

Viatris to Announce First Quarter 2026 Financial Results

Viatris to Announce First Quarter 2026 Financial Results
Trendline Trendline
FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul